SBI-087

Pfizer · Phase 2 active Small molecule

At a glance

Generic name	SBI-087
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis (PHASE1)
Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis (PHASE1)
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus (PHASE1)
Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SBI-087 CI brief — competitive landscape report
SBI-087 updates RSS · CI watch RSS
Pfizer portfolio CI